Reuters logo
RedHill Biopharma's bowel syndrome drug succeeds in mid-stage study
October 3, 2017 / 11:14 AM / 2 months ago

RedHill Biopharma's bowel syndrome drug succeeds in mid-stage study

Oct 3 (Reuters) - RedHill Biopharma Ltd said on Tuesday its drug to treat irritable bowel syndrome with diarrhea met the main goal in a mid-stage study.

The drug, Bekinda, showed improvement in stool consistency response in patients, when compared with a placebo.

Reporting by Divya Grover in Bengaluru; Editing by Bernard Orr

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below